中医药干预新型冠状病毒肺炎恢复期后遗症的研究进展

史锁芳; 张晓娜; 王博寒

doi:10.14148/j.issn.1672-0482.2021.0473

中医药干预新型冠状病毒肺炎恢复期后遗症的研究进展

doi: 10.14148/j.issn.1672-0482.2021.0473

1.
南京中医药大学附属医院/江苏省中医院，江苏南京 210029
2.
南京中医药大学第一临床医学院，江苏南京 210023

基金项目:

江苏省中医药管理局项目 BE2020617

江苏省科技厅项目 JSZYJ202002

详细信息

通讯作者:
史锁芳，男，教授，主任中医师，主要从事中医药治疗呼吸系统疾病及急性呼吸道传染病的研究，E-mail：jsssf2006@126.com

中图分类号: R254.3
计量
- 文章访问数: 762
- HTML全文浏览量: 106
- PDF下载量: 263
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-01
- 网络出版日期: 2021-12-21
- 刊出日期: 2021-05-10
- 发布日期: 2021-05-15

Progress on TCM Interventions of COVID-19 in Recovery Period

1.
The Affiliated Hospital of Nanjing University of Chinese Medicine/Jiangsu Hospital of Chinese Medicine, Nanjing, 210029, China
2.
The First School of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China

摘要

摘要: 新型冠状病毒肺炎(COVID-19)是由新型冠状病毒(SARS-CoV-2)感染引起的急性呼吸系统疾病，除引起肺部病变外，尚可引起肺外多系统损伤并持续至恢复期。中医药辨证论治，扶正祛邪兼顾，能有效改善COVID-19恢复期后遗症。从COVID-19恢复期后遗症研究现状及中医药干预思路进行综述，以期为进一步研究COVID-19恢复期后遗症及中医药干预思路提供借鉴。
- 新型冠状病毒肺炎 /
- 恢复期 /
- 后遗症 /
- 中医药
Abstract: COVID-19 is an acute respiratory disease caused by the infection of SARS-CoV-2. In addition to pulmonary lesions, it can also cause damage to multiple systems outside the lung. Traditional Chinese medicien (TCM) treatment based on syndrome differentiation can take account of both strengthening the body and eliminating evil, and thus effectively improve the sequelae of COVID-19 during the recovery period. This article summarizes the research status of COVID-19 recovery period and the intervention idea of TCM, in order to provide perspectives for further studies in the sequelae of COVID-19 and TCM interventions of COVID-19 during recovery period.
- COVID-19 /
- recovery /
- sequela /
- traditional Chinese medicine

HTML全文

参考文献(42)

[1]	DONG MZ, ZHANG J, MA XF, et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19[J]. Biomedicine Pharmacother, 2020, 131: 110678. doi: 10.1016/j.biopha.2020.110678
[2]	WANG K, CHEN W, ZHANG Z, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells[J]. Signal Transduct Target Ther. 2020, 5(1): 283. doi: 10.1038/s41392-020-00426-x
[3]	HAHN JN, KAUSHIK DK, YONG VW. The role of EMMPRIN in T cell biology and immunological diseases[J]. J Leukoc Biol, 2015, 98(1): 33-48. doi: 10.1189/jlb.3RU0215-045R
[4]	侯可可, 张娜, 李桃, 等. 新型冠状病毒肺炎不同时期CT表现及中性粒细胞/淋巴细胞比值、T淋巴细胞亚群变化[J]. 放射学实践, 2020, 35(3): 272-276. https://www.cnki.com.cn/Article/CJFDTOTAL-FSXS202003010.htm
[5]	ZHAO YM, SHANG YM, SONG WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery[J]. E Clin Med, 2020, 25: 100463. http://www.sciencedirect.com/science/article/pii/s2589537020302078
[6]	XU Z, SHI L, WANG YJ, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X
[7]	MINA A, VAN BESIEN K, PLATANIAS LC. Hematological manifestations of COVID-19[J]. Leuk Lymphoma, 2020, 61(12): 2790-2798. doi: 10.1080/10428194.2020.1788017
[8]	HARMER D, GILBERT M, BORMAN R, et al. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme[J]. FEBS Lett, 2002, 532(1/2): 107-110. http://europepmc.org/abstract/MED/12459472
[9]	PATEL KP, PATEL PA, VUNNAM RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19[J]. J Clin Virol, 2020, 128: 104386. doi: 10.1016/j.jcv.2020.104386
[10]	ZHANG C, SHI L, WANG FS. Liver injury in COVID-19: Management and challenges[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 428-430. doi: 10.1016/S2468-1253(20)30057-1
[11]	ZHENG YY, MA YT, ZHANG JY, et al. COVID-19 and the cardiovascular system[J]. Nat Rev Cardiol, 2020, 17(5): 259-260. doi: 10.1038/s41569-020-0360-5
[12]	ALWAQFI NR, IBRAHIM KS. COVID-19: An update and cardiac involvement[J]. J Cardiothorac Surg, 2020, 15(1): 1-6. doi: 10.1186/s13019-020-1051-3
[13]	MAO L, JIN H, WANG M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China[J]. JAMA Neurol, 2020, 77(6): 683-690. doi: 10.1001/jamaneurol.2020.1127
[14]	HIRSCH JS, NG JH, ROSS DW, et al. Acute kidney injury in patients hospitalized with COVID-19[J]. Kidney Int, 2020, 98(1): 209-218. doi: 10.1016/j.kint.2020.05.006
[15]	YANG M, CHEN S, HUANG B, et al. Pathological findings in the testes of COVID-19 patients: Clinical implications[J]. Eur Urol Focus, 2020, 6(5): 1124-1129. doi: 10.1016/j.euf.2020.05.009
[16]	彭平, 陈沐, 彭辉, 等. 广州市47例新型冠状病毒肺炎恢复期患者肺功能研究[J]. 中国热带医学, 2020, 20(11): 1041-1043. https://www.cnki.com.cn/Article/CJFDTOTAL-RDYX202011005.htm
[17]	SHAW B, DASKAREH M, GHOLAMREZANEZHAD A. The lingering manifestations of COVID-19 during and after convalescence: Update on long-term pulmonary consequences of coronavirus disease 2019 (COVID-19)[J]. Radiol Med, 2021, 126(1): 40-46. doi: 10.1007/s11547-020-01295-8
[18]	XIONG QT, XU M, LI J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study[J]. Clin Microbiol Infect, 2021, 27(1): 89-95. doi: 10.1016/j.cmi.2020.09.023
[19]	CARDA S, INVERNIZZI M, BAVIKATTE G, et al. COVID-19 pandemic. What should Physical and Rehabilitation Medicine specialists do? A clinician's perspective[J]. Eur J Phys Rehabil Med, 2020, 56(4): 515-524.
[20]	LI DG, JIN ML, BAO PT, et al. Clinical characteristics and results of semen tests among men with coronavirus disease 2019[J]. JAMA Netw Open, 2020, 3(5): e208292. doi: 10.1001/jamanetworkopen.2020.8292
[21]	史锁芳, 魏瑜, 熊侃, 等. 209例新型冠状病毒肺炎恢复期患者中医证型分布及其证治思考[J]. 中医学, 2020, 9(4): 319-326.
[22]	夏友宏, 周大勇. 98例新型冠状病毒肺炎中医证型及四诊动态分布特征[J]. 中医药临床杂志, 2020, 32(8): 1403-1406. https://www.cnki.com.cn/Article/CJFDTOTAL-AHLC202008001.htm
[23]	阎博华, 唐健元, 丁红, 等. 中医药促进新型冠状病毒肺炎恢复期康复临床研究方案[J]. 成都中医药大学学报, 2020, 43(1): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-CDZY202001001.htm
[24]	夏平, 王文华, 邹启才, 等. 健脾益气方药用于新型冠状病毒肺炎恢复期患者的价值[J]. 现代中西医结合杂志, 2020, 29(31): 3421-3426. doi: 10.3969/j.issn.1008-8849.2020.31.001
[25]	汪宗清, 聂红科, 李青璇, 等. 基于网络药理学探讨黄芪六君子汤治疗新冠肺炎恢复期的作用机制[J]. 山东科学, 2020, 33(5): 14-26. https://www.cnki.com.cn/Article/CJFDTOTAL-SDKX202005002.htm
[26]	史锁芳, 方祝元, 熊侃, 等. 扶土生金康复方治疗COVID-19恢复期肺脾不足证患者临床观察[J]. 南京中医药大学学报, 2020, 36(3): 281-285. https://www.cnki.com.cn/Article/CJFDTOTAL-NJZY202003002.htm
[27]	田野, 李瑞明, 任红微, 等. 生脉散用于新型冠状病毒肺炎恢复期治疗的可行性探讨[J]. 药物评价研究, 2020, 43(3): 378-383. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ202003003.htm
[28]	张佳, 李晓东. 基于数据挖掘的各地区新冠肺炎恢复期中医药组方用药规律研究[J]. 湖北中医药大学学报, 2020, 22(6), 117-121. https://www.cnki.com.cn/Article/CJFDTOTAL-HZXX202006033.htm
[29]	万旭英, 孟宪泽, 李军昌, 等. 光谷济生方治疗恢复期新型冠状病毒肺炎的临床效果[J]. 第二军医大学学报, 2020, 41(8): 813-817. https://www.cnki.com.cn/Article/CJFDTOTAL-DEJD202008002.htm
[30]	史锁芳, 方祝元, 熊侃, 等. 中医综合疗法治疗新型冠状病毒肺炎恢复期气阴两虚证30例临床研究[J]. 江苏中医药, 2021, 53(1): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202101012.htm
[31]	郑美玲, 黄慧敏, 董艳. 从"三因制宜"理论探析西南地区新型冠状病毒肺炎恢复期的辨证思路[J]. 四川中医, 2020, 38(7): 10-13. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY202007004.htm
[32]	何堂清, 丁齐又, 周亚娜, 等. 运用扶正透邪通络法治疗新冠肺炎恢复期验案3则[J]. 吉林中医药, 2020, 40(11): 1401-1404. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL202011002.htm
[33]	姜芬, 张华敏, 纪鑫毓, 等. 我国新型冠状病毒肺炎诊疗方案恢复期中医药组方用药规律挖掘与探讨[J]. 中国中医药图书情报杂志, 2020, 44(5): 1-6. doi: 10.3969/j.issn.2095-5707.2020.05.001
[34]	文利红, 万坤镇, 帅垠琦, 等. 清燥养荣汤在新型冠状病毒肺炎恢复期的应用[J]. 中药药理与临床, 2020, 36(2): 61-63. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL202002016.htm
[35]	杨先照, 杜宏波, 赫伟丽, 等. 新型冠状病毒肺炎恢复期的中医药干预策略[J]. 北京中医药大学学报, 2020, 43(5): 363-367. doi: 10.3969/j.issn.1006-2157.2020.05.002
[36]	陈良, 李光熙, 李修洋, 等. 基于仝小林院士脏腑风湿理论探讨新型冠状病毒肺炎康复期的中药治疗[J]. 云南中医学院学报, 2020, 43(2): 25-27. https://www.cnki.com.cn/Article/CJFDTOTAL-YNZY202002005.htm
[37]	周文俊, 戴韫, 黄睿, 等. 陈兴华教授雷火灸治疗新型冠状病毒肺炎恢复期的认识[J]. 辽宁中医药大学学报, 2021, 23(2), 146-150. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB202102032.htm
[38]	陈云, 张金霞. "天-地-人"三才灸法治疗复杂证型感冒发热的探索与经验: 关于新型冠状病毒肺炎早中期及康复期患者应用艾灸的思考与建议[J]. 山东中医杂志, 2020, 39(6): 538-543. https://www.cnki.com.cn/Article/CJFDTOTAL-SDZY202006002.htm
[39]	张晶滢, 范骏. 论六字诀在新型冠状病毒肺炎康复中的作用[J]. 医学争鸣, 2020, 11(3): 31-34. https://www.cnki.com.cn/Article/CJFDTOTAL-DSJY202003008.htm
[40]	程艳彬, 姚重界, 朱清广, 等. "抗疫强身功"参与新型冠状病毒肺炎出院患者康复期治疗的可行性分析[J]. 江苏中医药, 2020, 52(6): 64-67. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202006024.htm
[41]	韩杰, 徐曦, 周晶, 等. 导引功法防治新型冠状病毒肺炎的作用[J]. 中国中医药信息杂志, 2020, 27(8): 20-22. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202008006.htm
[42]	刘晓丹, 刘莉, 陆云飞, 等. 新型冠状病毒肺炎患者功能恢复的中西医结合康复训练指导建议[J]. 上海中医药杂志, 2020, 54(3): 9-13. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ202003004.htm